Literature DB >> 31931965

Surgical management of locally-advanced and metastatic hepatoblastoma.

Charissa M Lake1, Gregory M Tiao1, Alexander J Bondoc2.   

Abstract

Advanced stage hepatoblastoma, including both locally advanced primary tumors as well as metastatic disease, poses unique clinical challenges. Despite substantial advances in chemotherapeutics, surgical extirpation remains the mainstay of cure for this tumor. Locally advanced tumors that involve multiple hepatic lobes and/or invade significant vascular structures can be managed either by complex hepatic resections or liver transplantation. We review the indications, roles, and outcomes of these surgical approaches as well as those for the resection of pulmonary metastases.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extreme resection; Hepatoblastoma; Indocyanine green; Liver transplant; PRETEXT; Pulmonary metastasectomy

Year:  2019        PMID: 31931965     DOI: 10.1016/j.sempedsurg.2019.150856

Source DB:  PubMed          Journal:  Semin Pediatr Surg        ISSN: 1055-8586            Impact factor:   2.754


  9 in total

1.  Repeat hepatectomy for pediatric recurrent chemotherapy-resistant hepatoblastoma: a report of 18 cases.

Authors:  Xiaoran Li; Zheng Wang; Dongpo Zhang; Di Zhao; Jindong Ye; Weihong Duan; Liuxin Duan; Quanda Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-29       Impact factor: 4.322

2.  Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study.

Authors:  Howard M Katzenstein; Marcio H Malogolowkin; Mark D Krailo; Jin Piao; Alexander J Towbin; M Beth McCarville; Gregory M Tiao; Stephen P Dunn; Max R Langham; Eugene D McGahren; Milton J Finegold; Sarangarajan Ranganathan; Christopher B Weldon; Patrick A Thompson; Angela D Trobaugh-Lotrario; Allison F O'Neill; Wayne L Furman; Nadia Chung; Jessica Randazzo; Carlos Rodriguez-Galindo; Rebecka L Meyers
Journal:  Cancer       Date:  2021-11-11       Impact factor: 6.921

Review 3.  Current Approaches in Hepatoblastoma-New Biological Insights to Inform Therapy.

Authors:  Peng V Wu; Arun Rangaswami
Journal:  Curr Oncol Rep       Date:  2022-04-19       Impact factor: 5.945

Review 4.  A narrative review of the challenges and countermeasures in hepatoblastoma management during COVID-19 epidemic.

Authors:  Hang Xu; Yan Zhou; Rui Sun; Xuelai Liu; Mei Diao; Xianghai Ren; Long Li
Journal:  Transl Pediatr       Date:  2020-12

5.  Clinical Characteristics and Prognosis Analysis of Infantile Hepatoblastoma-A 15-Year Retrospective Single-Center Study.

Authors:  Tian Zhi; Weiling Zhang; Yi Zhang; Huimin Hu; Dongsheng Huang
Journal:  Cancer Manag Res       Date:  2021-04-13       Impact factor: 3.989

6.  IL-34 in hepatoblastoma cells potentially promote tumor progression via autocrine and paracrine mechanisms.

Authors:  Tomoaki Irie; Daiki Yoshii; Yoshihiro Komohara; Yukio Fujiwara; Masashi Kadohisa; Masaki Honda; Shinya Suzu; Toshiharu Matsuura; Kenichi Kohashi; Yoshinao Oda; Taizo Hibi
Journal:  Cancer Med       Date:  2022-02-08       Impact factor: 4.452

7.  Feasibility of Real-Time Central Surgical Review for Patients with Advanced-Stage Hepatoblastoma in the JPLT3 Trial.

Authors:  Tomoro Hishiki; Shohei Honda; Yuichi Takama; Yukihiro Inomata; Hideaki Okajima; Ken Hoshino; Tatsuya Suzuki; Ryota Souzaki; Motoshi Wada; Mureo Kasahara; Koichi Mizuta; Takaharu Oue; Akiko Yokoi; Takuro Kazama; Shugo Komatsu; Isamu Saeki; Osamu Miyazaki; Tetsuya Takimoto; Kohmei Ida; Kenichiro Watanabe; Eiso Hiyama
Journal:  Children (Basel)       Date:  2022-02-10

8.  Bone metastases in hepatoblastoma, an unusual presentation. Case report and review of the literature.

Authors:  Viviana Barragan; Maria Camila Escudero; Ivette C Jimenez; Catalina Correa; Juan Pablo Luengas
Journal:  Radiol Case Rep       Date:  2022-09-13

Review 9.  Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors.

Authors:  Qiyang Shen; Xingyu Liu; Wei Li; Xu Zhao; Tao Li; Kai Zhou; Jianfeng Zhou
Journal:  Front Genet       Date:  2022-01-18       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.